IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

New Horizon Health IPO: Poised for Growth

New Horizon Health IPO: Valuation Insights

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

New Horizon Health  / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a> is a leading player in China’s colorectal cancer screening market. It has two self-developed cancer screening tests - Pupu Tube and ColoClear. It will have a listing hearing for a $300 million Hong Kong IPO this week, according to press reports.</p><div class="content-highlight"><p>New Horizon is a play on the rapid growth of the cancer screening market in China, particularly the colorectal cancer screening market. Colorectal cancer is one of the deadliest cancer types in China, both by incidence and mortality rates. The colorectal cancer screening market in China is expected to grow significantly to be worth RMB19.8 billion in 2030 (18.7% CAGR between 2019 to 2030) due to the availability of more effective screening solutions and increased awareness of cancer screening, according to Frost &amp; Sullivan. We believe that New Horizon has the right ingredients to capitalise on this market opportunity. </p></div>

New Horizon Health (NHH HK) is a leading player in China’s colorectal cancer screening market. It has two self-developed cancer screening tests - Pupu Tube and ColoClear. It will have a listing hearing for a $300 million Hong Kong IPO this week, according to press reports.New Horizon is a play on the rapid growth of the cancer screening market in China, particularly the colorectal cancer screening market. Colorectal cancer is one of the deadliest cancer types in China, both by incidence and mortality rates. The colorectal cancer screening market in China is expected to grow significantly to be worth RMB19.8 billion in 2030 (18.7% CAGR between 2019 to 2030) due to the availability of more effective screening solutions and increased awareness of cancer screening, according to Frost &amp; Sullivan. We believe that New Horizon has the right ingredients to capitalise on this market opportunity. 

New Horizon Health IPO Initiation: Screening for Cancer